Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Gross Margin (2016 - 2025)

Heron Therapeutics' Gross Margin history spans 10 years, with the latest figure at 72.61% for Q4 2025.

  • For Q4 2025, Gross Margin fell 231.0% year-over-year to 72.61%; the TTM value through Dec 2025 reached 73.31%, up 9.0%, while the annual FY2025 figure was 73.31%, 9.0% up from the prior year.
  • Gross Margin reached 72.61% in Q4 2025 per HRTX's latest filing, up from 68.82% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 78.26% in Q1 2025 to a low of 0.86% in Q2 2021.
  • Average Gross Margin over 5 years is 54.85%, with a median of 54.77% recorded in 2022.
  • Peak YoY movement for Gross Margin: plummeted -5933bps in 2021, then surged 4060bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 47.03% in 2021, then increased by 23bps to 57.95% in 2022, then increased by 23bps to 71.12% in 2023, then rose by 5bps to 74.92% in 2024, then fell by -3bps to 72.61% in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Gross Margin are 72.61% (Q4 2025), 68.82% (Q3 2025), and 73.5% (Q2 2025).